{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:42:52Z","timestamp":1792705372290,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["234110"],"award-info":[{"award-number":["234110"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.msard.2023.105093","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T08:52:07Z","timestamp":1697791927000},"page":"105093","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Progression independent of relapses in aquaporin4-IgG-seropositive neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and multiple sclerosis"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0861-2178","authenticated-orcid":false,"given":"Negar","family":"Molazadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Akaishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gauruv","family":"Bose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanuja","family":"Chitnis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2023.105093_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2022.120269","article-title":"Follow-up of retinal thickness and optic MRI after optic neuritis in anti-MOG antibody-associated disease and anti-AQP4 antibody-positive NMOSD","volume":"437","author":"Akaishi","year":"2022","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2023.105093_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577467","article-title":"Progression pattern of neurological disability with respect to clinical attacks in anti-MOG antibody-associated disorders","volume":"351","author":"Akaishi","year":"2021","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.msard.2023.105093_bib0003","doi-asserted-by":"crossref","first-page":"13890","DOI":"10.1038\/s41598-020-70919-w","article-title":"Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders","volume":"10","author":"Akaishi","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.msard.2023.105093_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.875456","article-title":"Calculating and comparing the annualized relapse rate and estimating the confidence interval in relapsing neurological diseases","volume":"13","author":"Akaishi","year":"2022","journal-title":"Front. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2023.105093_bib0005","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol."},{"issue":"18","key":"10.1016\/j.msard.2023.105093_bib0006","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1212\/WNL.0000000000201263","article-title":"Frequency of New or Enlarging Lesions on MRI Outside of Clinical Attacks in Patients With MOG-Antibody-Associated Disease","volume":"99","author":"BS-M","year":"2022","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.msard.2023.105093_bib0007","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.37833","article-title":"Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder","volume":"4","author":"Camera","year":"2021","journal-title":"JAMA Netw. Open"},{"issue":"6","key":"10.1016\/j.msard.2023.105093_bib0008","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/ceo.12358","article-title":"Understanding and checking the assumptions of linear regression: a primer for medical researchers","volume":"42","author":"Casson","year":"2014","journal-title":"Clin. Exp. Ophthal."},{"issue":"2","key":"10.1016\/j.msard.2023.105093_bib0009","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ana.25957","article-title":"Silent New Brain MRI Lesions in Children with MOG-Antibody Associated Disease","volume":"89","author":"Fadda","year":"2021","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2023.105093_bib0010","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1097\/WNO.0000000000001282","article-title":"Optic Neuritis-Independent Retinal Atrophy in Neuromyelitis Optica Spectrum Disorder","volume":"42","author":"Filippatou","year":"2022","journal-title":"J. Neuroophthalmol."},{"issue":"8","key":"10.1016\/j.msard.2023.105093_bib0011","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.autrev.2006.02.012","article-title":"A model for the comprehensive investigation of a chronic autoimmune disease: the multiple sclerosis CLIMB study","volume":"5","author":"Gauthier","year":"2006","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.msard.2023.105093_bib0012","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00415-016-8333-7","article-title":"Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration","volume":"264","author":"Havla","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2023.105093_bib0013","article-title":"Assessment of definitions of sustained disease progression in relapsing-remitting multiple sclerosis","volume":"2013","author":"Healy","year":"2013","journal-title":"Mult. Scler. Int."},{"issue":"6","key":"10.1016\/j.msard.2023.105093_bib0014","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/ICU.0000000000000703","article-title":"Update on neuromyelitis optica spectrum disorder","volume":"31","author":"Holroyd","year":"2020","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.msard.2023.105093_bib0015","unstructured":"https:\/\/climbstudy.org."},{"key":"10.1016\/j.msard.2023.105093_bib0016","unstructured":"https:\/\/neurostatus.net."},{"issue":"1","key":"10.1016\/j.msard.2023.105093_bib0017","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflamm."},{"issue":"3","key":"10.1016\/j.msard.2023.105093_bib0018","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol."},{"issue":"11","key":"10.1016\/j.msard.2023.105093_bib0019","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2023.105093_bib0020","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/brain\/awac016","article-title":"How patients with multiple sclerosis acquire disability","volume":"145","author":"Lublin","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.msard.2023.105093_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577702","article-title":"Sotirchos ES. Evidence for and against subclinical disease activity and progressive disease in MOG antibody disease and neuromyelitis optica spectrum disorder","volume":"360","author":"Molazadeh","year":"2021","journal-title":"J. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.msard.2023.105093_bib0022","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/jim-2019-001126","article-title":"CNS inflammatory demyelinating disorders: MS, NMOSD and MOG antibody associated disease","volume":"68","author":"Rosenthal","year":"2020","journal-title":"J. Investig. Med."},{"issue":"2","key":"10.1016\/j.msard.2023.105093_bib0023","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.msard.2023.105093_bib0024","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ana.25463","article-title":"Silent progression in disease activity-free relapsing multiple sclerosis","volume":"85","author":"University of California","year":"2019","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2023.105093_bib0025","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3352\/jeehp.2013.10.12","article-title":"The retrospective chart review: important methodological considerations","volume":"10","author":"Vassar","year":"2013","journal-title":"J. Educ. Eval. Health Prof."},{"issue":"2","key":"10.1016\/j.msard.2023.105093_bib0026","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823005941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823005941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T01:22:13Z","timestamp":1724894533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823005941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":26,"alternative-id":["S2211034823005941"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.105093","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progression independent of relapses in aquaporin4-IgG-seropositive neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.105093","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105093"}}